- Tips for Spending Holiday Time With Family Members Who Live with Dementia
- Tainted Cucumbers Now Linked to 100 Salmonella Cases in 23 States
- Check Your Pantry, Lay’s Classic Potato Chips Recalled Due to Milk Allergy Risk
- Norovirus Sickens Hundreds on Three Cruise Ships: CDC
- Not Just Blabber: What Baby’s First Vocalizations and Coos Can Tell Us
- What’s the Link Between Memory Problems and Sexism?
- Supreme Court to Decide on South Carolina’s Bid to Cut Funding for Planned Parenthood
- Antibiotics Do Not Increase Risks for Cognitive Decline, Dementia in Older Adults, New Data Says
- A New Way to Treat Sjögren’s Disease? Researchers Are Hopeful
- Some Abortion Pill Users Surprised By Pain, Study Says
Lawsuit Against Makers of Ozempic, Mounjaro Claim Meds Caused ‘Stomach Paralysis’
A Louisiana woman is suing the makers of two type 2 diabetes drugs used off-label for obesity, saying they failed to adequately warn about the risk of severe stomach problems.
The lawsuit seeks “very significant” but unspecified compensation from the makers of both Ozempic and Mounjaro, said attorney Paul Pennock of the Orlando, Fla.-based firm Morgan & Morgan.
Pennock filed the lawsuit Wednesday on behalf of Jaclyn Bjorklund, 44, NBC News reported.
The lawsuit against Novo Nordisk and Eli Lilly claims Bjorklund was “severely injured” after taking the two diabetes drugs, which are part of a new class of medication called GLP-1 agonists.
Pennock said she is suffering “persistent” vomiting and severe gastroparesis, also known as stomach paralysis.
Gastroparesis slows or stops food from moving out of the stomach and into the small intestines. It can be caused by underlying medical issues, including diabetes, according to the American College of Gastroenterology. Infections and some medication can also cause it.
The GLP-1 agonists slow food’s movement and have been found to cause some GI issues in clinical trials. Those are listed as side effects on the drug labels.
Both Ozempic and Mounjaro have the phrase “delays gastric emptying” on their prescribing information, though they don’t specifically use the word “gastroparesis,” NBC News reported.
A U.S. Food and Drug Administration spokeswoman said it was unclear whether the GLP-1 medications contribute to gastroparesis.
“If newly identified safety signals are identified, the FDA will determine what actions are appropriate after a thorough review of the body of evidence,” spokeswoman Chanapa Tantibanchachai said in a statement.
Eli Lilly did not respond to an NBC News request for comment, and a Novo Nordisk spokeswoman said the company was unaware of the lawsuit.
“Patient safety is of utmost importance to Novo Nordisk,” said spokeswoman Natalia Salomao. “We recommend patients take these medications for their approved indications and under the supervision of a health care professional.”
More information
There’s more about GLP-1 agonists and weight loss at the Mayo Clinic.
SOURCE: NBC News
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.
Related
-
Some Abortion Pill Users Surprised By Pain, Study SaysAbortion pills are safe and effective, but some pain...
- December 20, 2024
-
FDA: Veozah, First Hormone-Free Hot Flash Drug, Issued Black Box WarningThe U.S. Food and Drug Administration (FDA) has issued...
- December 18, 2024
-
Non-heterosexual Women Report Better Sexual Functioning During MidlifeTUESDAY, Dec. 17, 2024 A woman’s sex drive often...
- December 18, 2024
-
Task Force Supports Women Over 30 Collecting Samples for Cervical Cancer ScreeningIn guidelines that may encourage more women to get...
- December 10, 2024
